Theravance Biopharma Q2 2026: Narrower Loss, 11% YUPELRI Growth, and Zymeworks Deal on Track
TBPH sits 53% above its 52-week low of $11.045 on elevated volume (4.3× avg).
Summary
Theravance Biopharma's Q2 2026 results featured an 11% increase in YUPELRI collaboration revenue, a narrowed net loss, and a strong cash position. The pending acquisition by Zymeworks for $17.00 per share plus a CVR is expected to close in the second half of 2026.
Key Events · Earnings and Guidance · TBPH
-
Q2 2026 Financial Results
A net loss of $5.9 million, or $0.11 per share, compared to net income of $54.8 million in Q2 2025—a figure that included a $75.1 million one-time gain. Revenue reached $20.7 million, all from the YUPELRI collaboration.
-
YUPELRI Revenue Growth
Collaboration revenue rose 11% year-over-year to $20.7 million, fueled by 7% growth in U.S. net sales to $70.7 million and improved operating leverage.
-
TRELEGY Milestone Payment
GSK reported Q2 2026 TRELEGY net sales of approximately $1.0 billion, and there is high confidence in achieving the $100 million milestone payment from Royalty Pharma for full-year 2026.
-
Restructuring Progress
Operating expenses, excluding restructuring and transaction costs, decreased 35% year-over-year in Q2 2026. Full run-rate savings of approximately $70 million are expected in the second half of 2026.
Analysis · TBPH · Life Sciences
A solid quarter for Theravance Biopharma, with YUPELRI collaboration revenue climbing 11% to $20.7 million and operating expenses slashed 35% year-over-year thanks to restructuring. The net loss narrowed to $5.9 million—a sharp contrast to the prior year's profit, which was inflated by a one-time gain. Bolstered by $387.7 million in cash and no debt, the balance sheet remains robust. The pending $17.00 per share acquisition by Zymeworks is on course for the second half of 2026, and high confidence in a $100 million TRELEGY milestone payment adds near-term upside. Together, these results strengthen the value proposition for shareholders ahead of the acquisition vote.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TBPH was trading at $16.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $877.5M. The 52-week trading range was $11.05 to $21.03. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.